RecruitingPhase 1NCT06818838

A Clinical Study Evaluating LY-M001 Injection in the Treatment of Adult Patients With Type I Gaucher Disease

Studying Gaucher disease type 1

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Lingyi Biotech Co., Ltd.
Principal Investigator: Fengkui Zhang, PhD
Hematology Hospital, Chinese Academy of Medical Sciences
Intervention: LY-M001(genetic)
Enrollment: 12 enrolled
Eligibility: 18-60 years · All sexes
Timeline: 2024 – 2027

Study locations (3)

Guangzhou First People's Hospital, Guangzhou, Guangdong, China
Shanxi Bethune Hospital, Taiyuan, Shanxi, China
Hematology Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin Municipality, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06818838 on ClinicalTrials.gov

Other trials for Gaucher disease type 1

Additional recruiting or active studies for the same condition.

ACTIVE NOT RECRUITINGPHASE2NCT02843035
Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension
Genzyme, a Sanofi Company

See all trials for Gaucher disease type 1 →

← Back to all trials